Systemic lupus erythematosus: Diagnosis and clinical management

Journal of Autoimmunity

Volumn 96, Issue , 2019, Pages 1-13

  Fava, Andrea ^a   Petri, Michelle ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Diagnosis; Management; Systemic lupus erythematosus

Indexed keywords

ANIFROLUMAB; ATACICEPT; AZATHIOPRINE; BARICITINIB; BELIMUMAB; BIOLOGICAL PRODUCT; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOPHOSPHAMIDE; HYDROXYCHLOROQUINE; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; MYCOPHENOLIC ACID; VITAMIN D; IMMUNOLOGIC FACTOR;

CENTRAL NERVOUS SYSTEM DISEASE; CLASSIFICATION; CLINICAL FEATURE; COMORBIDITY; CORONARY ARTERY DISEASE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DISEASE; LIFESTYLE MODIFICATION; MUSCULOSKELETAL DISEASE; NONHUMAN; OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; SKIN LUPUS ERYTHEMATOSUS; SYSTEMIC LUPUS ERYTHEMATOSUS; ANIMAL; LIFESTYLE; MOLECULARLY TARGETED THERAPY; ULTRAVIOLET RADIATION;

ANIMALS; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; LIFE STYLE; LUPUS ERYTHEMATOSUS, SYSTEMIC; MOLECULAR TARGETED THERAPY; ULTRAVIOLET RAYS; VITAMIN D;

EID: 85059230293     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2018.11.001     Document Type: Review

References (269)

1. Petri, M., Epidemiology of systemic lupus erythematosus. Best Pract. Res. Clin. Rheumatol. 16 (2002), 847–858, 10.1053/berh.2002.0259.
2. Johnson, A.E., Gordon, C., Palmer, R.G., Bacon, P.A., The prevalence and incidence of systemic lupus erythematosus in Birmingham, England: relationship to ethnicity and country of birth. Arthritis Rheum. 38 (1995), 551–558, 10.1002/art.1780380415.
3. Danchenko, N., Satia, J., Anthony, M., Epidemiology of systematic lupus erythematosus: a comparison of worldwide disease burden. Lupus 12 (2006), 308–318 http://lup.sagepub.com.proxygw.wrlc.org/content/15/5/308.full.pdf+html.
4. Symmons, D.P.M., Occasional series: lupus around the World frequency of lupus in people of African origin. Lupus 4 (1995), 176–178, 10.1177/096120339500400303.
5. Pons-Estel, G.J., Alarcón, G.S., Scofield, L., Reinlib, L., Cooper, G.S., Understanding the epidemiology and progression of systemic lupus erythematosus. Semin. Arthritis Rheum. 39 (2010), 257–268, 10.1016/j.semarthrit.2008.10.007.
6. Krishnan, E., Hubert, H.B., Ethnicity and mortality from systemic lupus erythematosus in the US. Ann. Rheum. Dis. 65 (2006), 1500–1505, 10.1136/ard.2005.040907.
7. Ferucci, E.D., Johnston, J.M., Gaddy, J.R., Sumner, L., Posever, J.O., Choromanski, T.L., Gordon, C., Lim, S.S., Helmick, C.G., Prevalence and incidence of systemic lupus erythematosus in a population-based registry of American Indian and Alaska Native people, 2007-2009. Arthr. Rheumatol. 66 (2014), 2494–2502, 10.1002/art.38720.
8. Lim, S.S., Bayakly, A.R., Helmick, C.G., Gordon, C., Easley, K.A., Drenkard, C., The incidence and prevalence of systemic lupus erythematosus, 2002-2004: the Georgia lupus registry. Arthr. Rheumatol. 66 (2014), 357–368, 10.1002/art.38239.
9. Somers, E.C., Marder, W., Cagnoli, P., Lewis, E.E., DeGuire, P., Gordon, C., Helmick, C.G., Wang, L., Wing, J.J., Dhar, J.P., Leisen, J., Shaltis, D., McCune, W.J., Population-based incidence and prevalence of systemic lupus erythematosus: the Michigan lupus epidemiology and surveillance program. Arthr. Rheumatol. 66 (2014), 369–378, 10.1002/art.38238.
10. Helmick, C.G., Felson, D.T., Lawrence, R.C., Gabriel, S., Hirsch, R., Kwoh, C.K., Liang, M.H., Kremers, H.M., Mayes, M.D., Merkel, P.A., Pillemer, S.R., Reveille, J.D., Stone, J.H., Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum. 58 (2008), 15–25, 10.1002/art.23177.
11. Tsokos, G.C., Lo, M.S., Reis, P.C., Sullivan, K.E., New insights into the immunopathogenesis of systemic lupus erythematosus. Nat. Rev. Rheumatol. 12 (2016), 716–730, 10.1038/nrrheum.2016.186.
12. Generali, E., Ceribelli, A., Stazi, M.A., Selmi, C., Lessons learned from twins in autoimmune and chronic inflammatory diseases. J. Autoimmun. 83 (2017), 51–61, 10.1016/j.jaut.2017.04.005.
13. Ghodke-Puranik, Y., Niewold, T.B., Immunogenetics of systemic lupus erythematosus: a comprehensive review. J. Autoimmun. 64 (2015), 125–136, 10.1016/j.jaut.2015.08.004.
14. Burger, R.A., Torres, A.R., Warren, R.P., Caldwell, V.D., Hughes, B.G., Echinacea-induced cytokine production by human macrophages. Int. J. Immunopharmacol. 19 (1997), 371–379, 10.1016/S0192-0561(97)00061-1.
15. Spelman, K., Burns, J.J., Nichols, D., Winters, N., Ottersberg, S., Tenborg, M., Modulation of cytokine expression by traditional medicines: a review of herbal immunomodulators. Altern. Med. Rev. 11 (2006), 128–150, 10.1016/j.cyto.2017.10.019.
16. Petri, M., Allbritton, J., Antibiotic allergy in systemic lupus erythematosus: a case-control study. J. Rheumatol. 19 (1992), 265–269 http://www.ncbi.nlm.nih.gov/pubmed/1629825.
17. Costenbader, K.H., Kim, D.J., Peerzada, J., Lockman, S., Nobles-Knight, D., Petri, M., Karlson, E.W., Cigarette smoking and the risk of systemic lupus erythematosus: a meta-analysis. Arthritis Rheum. 50 (2004), 849–857, 10.1002/art.20049.
18. Blomberg, J., Nived, O., Pipkorn, R., Bengtsson, A., Erlinge, D., Sturfelt, G., Increased antiretroviral antibody reactivity in sera from a defined population of patients with systemic lupus erythematosus: correlation with autoantibodies and clinical manifestations. Arthritis Rheum. 37 (1994), 57–66 http://www.ncbi.nlm.nih.gov/pubmed/7510483.
19. Cooper, G.S., Parks, C.G., Occupational and environmental exposures as risk factors for systemic lupus erythematosus. Curr. Rheumatol. Rep. 6 (2004), 367–374 http://www.ncbi.nlm.nih.gov/pubmed/15355749.
20. James, J.A., Neas, B.R., Moser, K.L., Hall, T., Bruner, G.R., Sestak, A.L., Harley, J.B., Systemic lupus erythematosus in adults is associated with previous Epstein-Barr virus exposure. Arthritis Rheum. 44 (2001), 1122–1126, 10.1002/1529-0131(200105)44:5<1122::AID-ANR193>3.0.CO;2-D.
21. Parks, C.G., Cooper, G.S., Nylander-French, L.A., Sanderson, W.T., Dement, J.M., Cohen, P.L., Dooley, M.A., Treadwell, E.L., Clair, E.W. St., Gilkeson, G.S., Hoppin, J.A., Savitz, D.A., Occupational exposure to crystalline silica and risk of systemic lupus erythematosus: a population-based, case-control study in the southeastern United States. Arthritis Rheum. 46 (2002), 1840–1850, 10.1002/art.10368.
22. Crowe, W., Allsopp, P.J., Watson, G.E., Magee, P.J., Strain, J.J., Armstrong, D.J., Ball, E., McSorley, E.M., Mercury as an environmental stimulus in the development of autoimmunity – a systematic review. Autoimmun. Rev. 16 (2017), 72–80, 10.1016/j.autrev.2016.09.020.
23. Zarmbinski, M.A., Messner, R.P., Mandel, J.S., Anti-dsDNA antibodies in laboratory workers handling blood from patients with systemic lupus erythematosus. J. Rheumatol., 19, 1992 1380–4 http://www.ncbi.nlm.nih.gov/pubmed/1433005.
24. Chiou, S.-H., Lan, J.-L., Lin, S.-L., Chen, D.-Y., Tsai, N.-Y., Kuan, C.-Y., Lin, T.-Y., Lin, F.-J., Lee, W.-M., Chang, T.-J., Pet dogs owned by lupus patients are at a higher risk of developing lupus. Lupus 13 (2004), 442–449, 10.1191/0961203303lu1039oa.
25. Song, H., Fang, F., Tomasson, G., Arnberg, F.K., Mataix-Cols, D., Fernández de la Cruz, L., Almqvist, C., Fall, K., Valdimarsdóttir, U.A., Association of stress-related disorders with subsequent autoimmune disease. Jama 319 (2018), 2388–2400, 10.1001/jama.2018.7028.
26. Roberts, A.L., Malspeis, S., Kubzansky, L.D., Feldman, C.H., Chang, S.-C., Koenen, K.C., Costenbader, K.H., Association of trauma and posttraumatic stress disorder with incident systemic lupus erythematosus in a longitudinal cohort of women. Arthr. Rheumatol. (Hoboken, N.J.). 69 (2017), 2162–2169, 10.1002/art.40222.
27. Crow, M.K., Etiology and Pathogenesis of Systemic Lupus Erythematosus. tenth ed., 2017, Elsevier Inc., 10.1016/B978-0-323-31696-5.00079-6.
28. Katsuyama, T., Tsokos, G.C., Moulton, V.R., Aberrant T cell signaling and subsets in systemic lupus erythematosus. Front. Immunol., 9, 2018, 10.3389/fimmu.2018.01088.
29. Baechler, E.C., Batliwalla, F.M., Karypis, G., Gaffney, P.M., a Ortmann, W., Espe, K.J., Shark, K.B., Grande, W.J., Hughes, K.M., Kapur, V., Gregersen, P.K., Behrens, T.W., Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc. Natl. Acad. Sci. U. S. A. 100 (2003), 2610–2615, 10.1073/pnas.0337679100.
30. Bennett, L., Palucka, A.K., Arce, E., Cantrell, V., Borvak, J., Banchereau, J., Pascual, V., Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J. Exp. Med. 197 (2003), 711–723, 10.1084/jem.20021553.
31. Kirou, K.A., Lee, C., George, S., Louca, K., Papagiannis, I.G., Peterson, M.G.E., Ly, N., Woodward, R.N., Fry, K.E., Lau, A.Y.-H., Prentice, J.G., Wohlgemuth, J.G., Crow, M.K., Coordinate overexpression of interferon-?-induced genes in systemic lupus erythematosus. Arthritis Rheum. 50 (2004), 3958–3967 http://doi.wiley.com/10.1002/art.20798.
32. Kaplan, M.J., Radic, M., Neutrophil extracellular traps: double-edged swords of innate immunity. J. Immunol. 189 (2012), 2689–2695, 10.4049/jimmunol.1201719.
33. Garcia-Romo, G.S., Caielli, S., Vega, B., Connolly, J., Allantaz, F., Xu, Z., Punaro, M., Baisch, J., Guiducci, C., Coffman, R.L., Barrat, F.J., Banchereau, J., Pascual, V., Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus. Sci. Transl. Med., 3, 2011, 10.1126/scitranslmed.3001201.
34. Lande, R., Ganguly, D., Facchinetti, V., Frasca, L., Conrad, C., Gregorio, J., Meller, S., Chamilos, G., Sebasigari, R., Riccieri, V., Bassett, R., Amuro, H., Fukuhara, S., Ito, T., Liu, Y.J., Gilliet, M., Neutrophils activate plasmacytoid dendritic cells by releasing self-DNA peptide complexes in systemic lupus erythematosus. Sci. Transl. Med., 3, 2011, 10.1126/scitranslmed.3001180 73ra19-73ra19.
35. Hakkim, A., Fürnrohr, B.G., Amann, K., Laube, B., Abed, U.A., Brinkmann, V., Herrmann, M., Voll, R.E., Zychlinsky, A., Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis. Proc. Natl. Acad. Sci. U. S. A. 107 (2010), 9813–9818 http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=20439745&retmode=ref&cmd=prlinks.
36. Leffler, J., Ciacma, K., Gullstrand, B., Bengtsson, A.A., Martin, M., Blom, A.M., A subset of patients with systemic lupus erythematosus fails to degrade DNA from multiple clinically relevant sources. Arthritis Res. Ther., 17, 2015, 205, 10.1186/s13075-015-0726-y.
37. a Casciola-Rosen, L., Anhalt, G., Rosen, a, Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. J. Exp. Med. 179 (1994), 1317–1330, 10.1084/jem.179.4.1317.
38. Casciola-Rosen, L., Rosen, A., Petri, M., Schlissel, M., Surface blebs on apoptotic cells are sites of enhanced procoagulant activity: implications for coagulation events and antigenic spread in systemic lupus erythematosus. Proc. Natl. Acad. Sci. U. S. A. 93 (1996), 1624–1629, 10.1073/pnas.93.4.1624.
39. Lehmann, P., Homey, B., Clinic and pathophysiology of photosensitivity in lupus erythematosus. Autoimmun. Rev. 8 (2009), 456–461, 10.1016/j.autrev.2008.12.012.
40. Guiducci, C., Gong, M., Xu, Z., Gill, M., Chaussabel, D., Meeker, T., Chan, J.H., Wright, T., Punaro, M., Bolland, S., Soumelis, V., Banchereau, J., Coffman, R.L., Pascual, V., Barrat, F.J., TLR recognition of self nucleic acids hampers glucocorticoid activity in lupus. Nature 465 (2010), 937–941, 10.1038/nature09102.
41. Paidassi, H., Tacnet-Delorme, P., Garlatti, V., Darnault, C., Ghebrehiwet, B., Gaboriaud, C., Arlaud, G.J., Frachet, P., C1q binds phosphatidylserine and likely acts as a multiligand-bridging molecule in apoptotic cell recognition. J. Immunol. 180 (2008), 2329–2338, 10.4049/jimmunol.180.4.2329.
42. Ehrenstein, M.R., Notley, C.A., The importance of natural IgM: scavenger, protector and regulator. Nat. Rev. Immunol. 10 (2010), 778–786, 10.1038/nri2849.
43. Thompson, R.A., Haeney, M., Reid, K.B.M., Davies, J.G., White, R.H.R., Cameron, A.H., A genetic defect of the C1q subcomponent of complement associated with childhood (immune complex) nephritis. N. Engl. J. Med. 303 (1980), 22–24, 10.1056/NEJM198007033030107.
44. Sisirak, V., Sally, B., D'Agati, V., Martinez-Ortiz, W., Özçakar, Z.B., David, J., Rashidfarrokhi, A., Yeste, A., Panea, C., Chida, A.S.S., Bogunovic, M., Ivanov, I.I.I., Quintana, F.J.J., Sanz, I., Elkon, K.B.B., Tekin, M., Yalçınkaya, F., Cardozo, T.J.J., Clancy, R.M.M., Buyon, J.P.P., Reizis, B., Digestion of chromatin in apoptotic cell microparticles prevents autoimmunity. Cell 166 (2016), 88–101, 10.1016/j.cell.2016.05.034.
45. Lo, M.S., Monogenic lupus. Curr. Rheumatol. Rep. 18 (2016), 1–7, 10.1007/s11926-016-0621-9.
46. Tan, E.M., Cohen, A.S., Fries, J.F., Masi, A.T., Mcshane, D.J., Rothfield, N.F., Schaller, J.G., Talal, N., Winchester, R.J., The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 25 (1982), 1271–1277, 10.1002/art.1780251101.
47. Hochberg, M.C., Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum., 40, 1997, 1725, 10.1002/1529-0131(199709)40:9<1725::AID-ART29>3.0.CO;2-Y.
48. Petri, M., Orbai, A.-M., Alarcón, G.S., et al. Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 64 (2012), 2677–2686, 10.1002/art.34473.Derivation.
49. Tedeschi, S.K., Johnson, S.R., Boumpas, D., Daikh, D., Dörner, T., Jayne, D., Kamen, D., Lerstrøm, K., Mosca, M., Ramsey-Goldman, R., Sinnette, C., Wofsy, D., Smolen, J.S., Naden, R.P., Aringer, M., Costenbader, K.H., Developing and refining new candidate criteria for systemic lupus erythematosus classification: an international collaboration. Arthritis Care Res. 70 (2018), 571–581, 10.1002/acr.23317.
50. Petri, M., Goldman, D., Magder, L.S., Validation of proposed EULAR/acr SLE classification criteria versus SLICC SLE classification criteria. Arthr. Rheumatol., 70(suppl), 2018.
51. Hartman, E.A.R., van Royen-Kerkhof, A., Jacobs, J.W.G., Welsing, P.M.J., Fritsch-Stork, R.D.E., Performance of the 2012 Systemic Lupus International Collaborating Clinics classification criteria versus the 1997 American College of Rheumatology classification criteria in adult and juvenile systemic lupus erythematosus. A systematic review and meta-an. Autoimmun. Rev. 17 (2018), 316–322, 10.1016/j.autrev.2018.01.007.
52. Wallace, D., Hahn, B.H., Dubois' Lupus Erythematosus and Related Syndromes. eighth ed., 2012, Saunders.
53. Firestein, G.S., Budd, R.C., Gabriel, S., McInnes, I.B., O'Dell, J., Kelley and Firestein's Textbook of Rheumatology. tenth ed., 2016, Elsevier.
54. Hejazi, E.Z., Werth, V.P., Cutaneous lupus erythematosus: an update on pathogenesis, diagnosis and treatment. Am. J. Clin. Dermatol. 17 (2016), 135–146, 10.1007/s40257-016-0173-9.
55. Walling, H.W., Sontheimer, R.D., Cutaneous lupus erythematosus: issues in diagnosis and treatment. Am. J. Clin. Dermatol. 10 (2009), 365–381, 10.2165/11310780-000000000-00000.
56. Hasan, T., Nyberg, F., Stephansson, E., Puska, P., Hakkinen, M., Sarna, S., Ros, A.-M., Ranki, A., Photosensitivity in lupus erythematosus, UV photoprovocation results compared with history of photosensitivity and clinical findings. Br. J. Dermatol. 136 (1997), 699–705, 10.1046/j.1365-2133.1997.6591644.x.
57. Sanders, C.J.G., Van Weelden, H., Kazzaz, G.A.A., Sigurdsson, V., Toonstra, J., Bruijnzeel-Koomen, C.A.F.M., Photosensitivity in patients with lupus erythematosus: a clinical and photobiological study of 100 patients using a prolonged phototest protocol. Br. J. Dermatol. 149 (2003), 131–137, 10.2165/11591790-000000000-00000.
58. Kuhn, A., Sonntag, M., Richter-Hintz, D., Oslislo, C., Megahed, M., Ruzicka, T., Lehmann, P., Phototesting in lupus erythematosus: a 15-year experience. J. Am. Acad. Dermatol. 45 (2001), 86–95, 10.1067/mjd.2001.114589.
59. Zandman-Goddard, G., Solomon, M., Rosman, Z., Peeva, E., Shoenfeld, Y., Environment and lupus-related diseases. Lupus 21 (2012), 241–250, 10.1177/0961203311426568.
60. Alarcon Segovia, D., Cetina, J.A., Lupus hair. Am. J. Med. Sci. 267 (1974), 241–242, 10.1039/c5ra13683k.
61. Miot, H.A., Miot, L.D.B., Haddad, G.R., Association between discoid lupus erythematosus and cigarette smoking: a case-control study. Dermatology 211 (2005), 118–122, 10.1159/000086440.
62. Böckle, B.C., Sepp, N.T., Smoking is highly associated with discoid lupus erythematosus and lupus erythematosus tumidus: analysis of 405 patients. Lupus 24 (2015), 669–674, 10.1177/0961203314559630.
63. Piette, E.W., Foering, K.P., Chang, A.Y., Okawa, J., Ten Have, T.R., Feng, R., Werth, V.P., Impact of smoking in cutaneous lupus erythematosus. Arch. Dermatol. 148 (2012), 317–322, 10.1001/archdermatol.2011.342.
64. Chasset, F., Francès, C., Barete, S., Amoura, Z., Arnaud, L., Influence of smoking on the efficacy of antimalarials in cutaneous lupus: a meta-analysis of the literature. J. Am. Acad. Dermatol. 72 (2015), 634–639, 10.1016/j.jaad.2014.12.025.
65. Petri, M., Musculoskeletal complications of systemic lupus erythematosus in the Hopkins Lupus Cohort: an update. Arthritis Care Res. 8 (1995), 137–145 http://www.ncbi.nlm.nih.gov/pubmed/7654797.
66. Grossman, J.M., Lupus arthritis. Best Pract. Res. Clin. Rheumatol. 23 (2009), 495–506, 10.1016/j.berh.2009.04.003.
67. Budhram, A., Chu, R., Rusta-Sallehy, S., Ioannidis, G., Denburg, J.A., Adachi, J.D., Haaland, D.A., Anti-cyclic citrullinated peptide antibody as a marker of erosive arthritis in patients with systemic lupus erythematosus: a systematic review and meta-analysis. Lupus 23 (2015), 1156–1163, 10.1177/0961203314540967.
68. Lins, C.F., Santiago, M.B., Ultrasound evaluation of joints in systemic lupus erythematosus: a systematic review. Eur. Radiol. 25 (2015), 2688–2692, 10.1007/s00330-015-3670-y.
69. Ostendorf, B., Scherer, A., Specker, C., Mödder, U., Schneider, M., Jaccoud's arthropathy in systemic lupus erythematosus: differentiation of deforming and erosive patterns by magnetic resonance imaging. Arthritis Rheum. 48 (2003), 157–165, 10.1002/art.10753.
70. Zollars, E.S., Hyer, M., Wolf, B., Chapin, R., Measuring lupus arthritis activity using contrasted high-field MRI. Associations with clinical measures of disease activity and novel patterns of disease. Lupus Sci. Med., 5, 2018, e000264, 10.1136/lupus-2018-000264.
71. Wolfe, F., Petri, M., Alarcón, G.S., Goldman, J., Chakravarty, E.F., Katz, R.S., Karlson, E.W., Fibromyalgia, systemic lupus erythematosus (SLE), and evaluation of SLE activity. J. Rheumatol. 36 (2008), 82–88, 10.3899/jrheum.080212.
72. Petri, M., Naqibuddin, M., Carson, K.A., Wallace, D.J., Weisman, M.H., Holliday, S.L., Sampedro, M., Padilla, P.A., Brey, R.L., Depression and cognitive impairment in newly diagnosed systemic lupus erythematosus. J. Rheumatol. 37 (2010), 2032–2038, 10.3899/jrheum.091366.
73. Bastian, H.M., Roseman, J.M., Mcgwin, G., Alarcón, G.S., Friedman, A.W., Fessler, B.J., Baethge, B.A., Reveille, J.D., Systemic lupus erythematosus in three ethnic groups. XII. Risk factors for lupus nephritis after diagnosis. Lupus 11 (2002), 152–160, 10.1191/0961203302lu158oa.
74. Bernatsky, S., Boivin, J.F., Joseph, L., Manzi, S., Ginzler, E., Gladman, D.D., Urowitz, M., Fortin, P.R., Petri, M., Barr, S., Gordon, C., Bae, S.C., Isenberg, D., Zoma, A., Aranow, C., Dooley, M.A., Nived, O., Sturfelt, G., Steinsson, K., Alarcón, G., Senécal, J.L., Zummer, M., Hanly, J., Ensworth, S., Pope, J., Edworthy, S., Rahman, A., Sibley, J., El-Gabalawy, H., McCarthy, T., Pierre, Y. St., Clarke, A., Ramsey-Goldman, R., Mortality in systemic lupus erythematosus. Arthritis Rheum. 54 (2006), 2550–2557, 10.1002/art.21955.
75. Faurschou, M., Starklint, H., Halberg, P., Jacobsen, S., Prognostic factors in lupus nephritis: diagnostic and therapeutic delay increases the risk of terminal renal failure. J. Rheumatol. 33 (2006), 1563–1569.
76. Wakasugi, D., Gono, T., Kawaguchi, Y., Hara, M., Koseki, Y., Katsumata, Y., Hanaoka, M., Yamanaka, H., Frequency of class III and IV nephritis in systemic lupus erythematosus without clinical renal involvement: an analysis of predictive measures. J. Rheumatol. 39 (2012), 79–85, 10.3899/jrheum.110532.
77. Christopher-Stine, L., Siedner, M., Lin, J., Haas, M., Parekh, H., Petri, M., Fine, D.M., Renal biopsy in lupus patients with low levels of proteinuria. J. Rheumatol. 34 (2007), 332–335.
78. Christopher-Stine, L., Petri, M., Astor, B.C., Fine, D., Urine protein-to-creatinine ratio is a reliable measure of proteinuria in lupus nephritis. J. Rheumatol. 31 (2004), 1557–1559 http://www.ncbi.nlm.nih.gov/pubmed/15290735.
79. Olson, S.W., Lee, J.J., Prince, L.K., Baker, T.P., Papadopoulos, P., Edison, J., Abbott, K.C., Elevated subclinical double-stranded DNA antibodies and future proliferative lupus nephritis. Clin. J. Am. Soc. Nephrol. 8 (2013), 1702–1708, 10.2215/CJN.01910213.
80. Orbai, A.-M., Truedsson, L., Sturfelt, G., Nived, O., Fang, H., Alarcón, G., Gordon, C., Merrill, J., Fortin, P., Bruce, I., Isenberg, D., Wallace, D., Ramsey-Goldman, R., Bae, S.-C., Hanly, J., Sanchez-Guerrero, J., Clarke, A., Aranow, C., Manzi, S., Urowitz, M., Gladman, D., Kalunian, K., Costner, M., Werth, V., Zoma, A., Bernatsky, S., Ruiz-Irastorza, G., Khamashta, M., Jacobsen, S., Buyon, J., Maddison, P., Dooley, M., Van Vollenhoven, R., Ginzler, E., Stoll, T., Peschken, C., Jorizzo, J., Callen, J., Lim, S., Fessler, B., Inanc, M., Kamen, D., Rahman, A., Steinsson, K., Franks, A., Sigler, L., Hameed, S., Pham, N., Brey, R., Weisman, M., McGwin, G., Magder, L., Petri, M., Anti-C1q antibodies in systemic lupus erythematosus. Lupus, 24, 2014, 10.1177/0961203314547791 pii: 0961203314547791.
81. Akhter, E., Burlingame, R., Seaman, A., Magder, L., Petri, M., Anti-C1q antibodies have higher correlation with flares of lupus nephritis than other serum markers. Lupus 20 (2011), 1267–1274, 10.1177/0961203311411597.
82. Stojan, G., Petri, M., Anti-C1q in systemic lupus erythematosus. Lupus 25 (2016), 873–877, 10.1177/0961203316645205.
83. Weening, J.J., D'agati, V.D., Schwartz, M.M., Seshan, S.V., Alpers, C.E., Appel, G.B., Balow, J.E., Bruijn, J.A.N.A., Cook, T., Ferrario, F., Fogo, A.B., Ginzler, E.M., Hebert, L.E.E., Hill, G., Hill, P., Jennette, J.C., Kong, N.C., Lesavre, P., Lockshin, M., Looi, L.-M., Makino, H., Moura, L.A., Nagata, M., The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int. 65 (2004), 521–530, 10.1111/j.1523-1755.2004.00443.x.
84. Shea-Simonds, P., Cairns, T.D., Roufosse, C., Cook, T., Vyse, T.J., Lupus podocytopathy. Rheumatology 48 (2009), 1616–1618, 10.1093/rheumatology/kep256.
85. Descombes, E., Droz, D., Drouet, L., Grünfeld, J.P., Lesavre, P., Renal vascular lesions in lupus nephritis. Medicine (Baltimore) 76 (1997), 355–368 http://www.ncbi.nlm.nih.gov/pubmed/9352738.
86. Salvatore, S.P., Barisoni, L.M.C., Herzenberg, A.M., Chander, P.N., Nickeleit, V., Seshan, S.V., Collapsing glomerulopathy in 19 patients with systemic lupus erythematosus or Lupus-like disease. Clin. J. Am. Soc. Nephrol. 7 (2012), 914–925, 10.2215/CJN.11751111.
87. Ainiala, H., Hietaharju, A., Loukkola, J., Peltola, J., Korpela, M., Metsänoja, R., Auvinen, A., Validity of the new American College of Rheumatology criteria for neuropsychiatric lupus syndromes: a population‐based evaluation. Arthritis Rheum. 45 (2001), 419–423, 10.1016/j.measurement.2013.09.007.
88. Petri, M., Orbai, A.M., Alarcõn, G.S., Gordon, C., Merrill, J.T., Fortin, P.R., Bruce, I.N., Isenberg, D., Wallace, D.J., Nived, O., Sturfelt, G., Ramsey-Goldman, R., Bae, S.C., Hanly, J.G., Sánchez-Guerrero, J., Clarke, A., Aranow, C., Manzi, S., Urowitz, M., Gladman, D., Kalunian, K., Costner, M., Werth, V.P., Zoma, A., Bernatsky, S., Ruiz-Irastorza, G., Khamashta, M.A., Jacobsen, S., Buyon, J.P., Maddison, P., Dooley, M.A., Van Vollenhoven, R.F., Ginzler, E., Stoll, T., Peschken, C., Jorizzo, J.L., Callen, J.P., Lim, S.S., Fessler, B.J., Inanc, M., Kamen, D.L., Rahman, A., Steinsson, K., Franks, A.G., Sigler, L., Hameed, S., Fang, H., Pham, N., Brey, R., Weisman, M.H., McGwin, G., Magder, L.S., Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 64 (2012), 2677–2686, 10.1002/art.34473.
89. Sibbitt, W.L., Sibbitt, R.R., Brooks, W.M., Neuroimaging in neuropsychiatric systemic lupus erythematosus. Arthritis Rheum. 42 (1999), 2026–2038, 10.1002/1529-0131(199910)42:10<2026::AID-ANR2>3.0.CO;2-J.
90. Birnbaum, J., Petri, M., Thompson, R., Izbudak, I., Kerr, D., Distinct subtypes of myelitis in systemic lupus erythematosus. Arthritis Rheum. 60 (2009), 3378–3387, 10.1002/art.24937.
91. Miller, D.H., Buchanan, N., Barker, G., Morrissey, S.P., Kendall, B.E., Rudge, P., Khamashta, M., Hughes, G.R., McDonald, W.I., Gadolinium-enhanced magnetic resonance imaging of the central nervous system in systemic lupus erythematosus. J. Neurol. 239 (1992), 460–464 1447575.
92. Sibbitt, W.L., Brooks, W.M., Haseler, L.J., Griffey, R.H., Frank, L.M., Hart, B.L., Sibbitt, R.R., Spin-spin relaxation of brain tissues in systemic lupus erythematosus. Arthritis Rheum. 38 (1995), 810–818, 10.1002/art.1780380615.
93. West, S.G., Emlen, W., Wener, M.H., Kotzin, B.L., Neuropsychiatric lupus erythematosus: a 10-year prospective study on the value of diagnostic tests. Am. J. Med. 99 (1995), 153–163, 10.1016/S0002-9343(99)80135-1.
94. Carbotte, R.M., Denburg, S.D., Denburg, J.A., Prevalence of cognitive impairment in systemic lupus erythematosus. J. Nerv. Ment. Dis. 174 (1986), 357–364 http://www.ncbi.nlm.nih.gov/pubmed/3711879.
95. Kozora, E., Ellison, M.C., West, S., Reliability and validity of the proposed American College of Rheumatology neuropsychological battery for systemic lupus erythematosus. Arthritis Care Res. 51 (2004), 810–818, 10.1002/art.20692.
96. Petri, M., Naqibuddin, M., Carson, K.A., Sampedro, M., Wallace, D.J., Weisman, M.H., Holliday, S.L., Padilla, P.A., Brey, R.L., Cognitive function in a systemic lupus erythematosus inception cohort. J. Rheumatol. 35 (2008), 1776–1781 08/13/0716 [pii].
97. Petri, M., Naqibuddin, M., Carson, K.A., Wallace, D.J., Weisman, M.H., Holliday, S.L., Sampedro, M., Padilla, P.A., Brey, R.L., Depression and cognitive impairment in newly diagnosed systemic lupus erythematosus. J. Rheumatol. 37 (2010), 2032–2038, 10.3899/jrheum.091366.
98. Leadbetter, E.A., Rifkin, I.R., Hohlbaum, A.M., Beaudette, B.C., Shlomchik, M.J., Marshak-Rothstein, A., Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 416 (2002), 603–607, 10.1038/416603a.
99. Means, T.K., Latz, E., Hayashi, F., Murali, M.R., Golenbock, D.T., Luster, A.D., Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9. J. Clin. Invest. 115 (2005), 407–417, 10.1172/JCI23025.
100. Kuznik, A., Bencina, M., Svajger, U., Jeras, M., Rozman, B., Jerala, R., Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines. J. Immunol. 186 (2011), 4794–4804, 10.4049/jimmunol.1000702.
101. Lafyatis, R., York, M., Marshak-Rothstein, A., Antimalarial agents: closing the gate on toll-like receptors?. Arthritis Rheum. 54 (2006), 3068–3070, 10.1002/art.22157.
102. Petri, M., Hydroxychloroquine use in the Baltimore Lupus Cohort: effects on lipids, glucose and thrombosis. Lupus 5:Suppl 1 (1996), S16–S22 http://www.ncbi.nlm.nih.gov/pubmed/8803905.
103. Fox, R., Anti-malarial drugs: possible mechanisms of action in autoimmune disease and prospects for drug development. Lupus 5:Suppl 1 (1996), S4–S10 http://www.ncbi.nlm.nih.gov/pubmed/8803903.
104. Wozniacka, A., Lesiak, A., Narbutt, J., McCauliffe, D.P., Sysa-Jedrzejowska, A., Chloroquine treatment influences proinflammatory cytokine levels in systemic lupus erythematosus patients. Lupus 15 (2006), 268–275, 10.1191/0961203306lu2299oa.
105. An, J., Woodward, J.J., Sasaki, T., Minie, M., Elkon, K.B., Cutting edge: antimalarial drugs inhibit IFN-β production through blockade of cyclic GMP-AMP synthase–DNA interaction. J. Immunol. 194 (2015), 4089–4093, 10.4049/jimmunol.1402793.
106. Alarcón, G.S., McGwin, G., Bertoli, A.M., Fessler, B.J., Calvo-Alén, J., Bastian, H.M., Vilà, L.M., Reveille, J.D., Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L). Ann. Rheum. Dis. 66 (2007), 1168–1172, 10.1136/ard.2006.068676.
107. Ruiz-Irastorza, G., Egurbide, M.-V., Pijoan, J.-I., Garmendia, M., Villar, I., Martinez-Berriotxoa, A., Erdozain, J.-G., Aguirre, C., Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. Lupus 15 (2006), 577–583, 10.1177/0961203306071872.
108. Ruiz-Irastorza, G., Ramos-Casals, M., Brito-Zeron, P., Khamashta, M.A., Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann. Rheum. Dis. 69 (2010), 20–28, 10.1136/ard.2008.101766.
109. Mok, C.C., Tse, S.M., Chan, K.L., Ho, L.Y., Effect of immunosuppressive therapies on survival of systemic lupus erythematosus: a propensity score analysis of a longitudinal cohort. Lupus 27 (2018), 722–727, 10.1177/0961203317739129.
110. Canadian Hydroxychloroquine Study Group, A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N. Engl. J. Med. 324 (1991), 150–154, 10.1056/NEJM199101173240303.
111. Fessler, B.J., Alarcón, G.S., McGwin, G., Roseman, J., Bastian, H.M., Friedman, A.W., Baethge, B.A., Vilá, L., Reveille, J.D., Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. Arthritis Rheum. 52 (2005), 1473–1480, 10.1002/art.21039.
112. Fasano, S., Pierro, L., Pantano, I., Iudici, M., Valentini, G., Longterm hydroxychloroquine therapy and low-dose aspirin may have an additive effectiveness in the primary prevention of cardiovascular events in patients with systemic lupus erythematosus. J. Rheumatol. 44 (2017), 1032–1038, 10.3899/jrheum.161351.
113. Kasitanon, N., Fine, D.M., Haas, M., Magder, L.S., Petri, M., Hydroxychloroquine use predicts complete renal remission within 12 months among patients treated with mycophenolate mofetil therapy for membranous lupus nephritis. Lupus 15 (2006), 366–370, 10.1191/0961203306lu2313oa.
114. Hanly, J.G., Urowitz, M.B., Su, L., Gordon, C., Bae, S.-C., Sanchez-Guerrero, J., Romero-Diaz, J., Wallace, D.J., Clarke, A.E., Ginzler, E., Merrill, J.T., Isenberg, D.A., Rahman, A., Petri, M., Fortin, P.R., Gladman, D., Bruce, I.N., Steinsson, K., Dooley, M., Khamashta, M.A., Alarcón, G.S., Fessler, B.J., Ramsey-Goldman, R., Manzi, S., Zoma, A.A., Sturfelt, G.K., Nived, O., Aranow, C., Mackay, M., Ramos-Casals, M., van Vollenhoven, R., Kalunian, K.C., Ruiz-Irastorza, G., Lim, S., Kamen, D.L., Peschken, C.A., Inanc, M., Theriault, C., Thompson, K., Farewell, V., Seizure disorders in systemic lupus erythematosus results from an international, prospective, inception cohort study. Ann. Rheum. Dis. 71 (2012), 1502–1509, 10.1136/annrheumdis-2011-201089.
115. Andrade, R.M., Alarcón, G.S., González, L.A., Fernández, M., Apte, M., Vilá, L.M., McGwin, G., Reveille, J.D., Seizures in patients with systemic lupus erythematosus: data from LUMINA, a multiethnic cohort (LUMINA LIV). Ann. Rheum. Dis. 67 (2008), 829–834, 10.1136/ard.2007.077594.
116. González, L.A., Pons-Estel, G.J., Zhang, J., Vilá, L.M., Reveille, J.D., Alarcón, G.S., Time to neuropsychiatric damage occurrence in LUMINA (LXVI): a multi-ethnic lupus cohort. Lupus 18 (2009), 822–830, 10.1177/0961203309104392.
117. Ruzicka, T., Sommerburg, C., Goerz, G., Kind, P., Mensing, H., Treatment of cutaneous lupus erythematosus with acitretin and hydroxychloroquine. Br. J. Dermatol. 127 (1992), 513–518 http://www.ncbi.nlm.nih.gov/pubmed/1467292.
118. Kuhn, A., Ruland, V., Bonsmann, G., Cutaneous lupus erythematosus: update of therapeutic options: Part i. J. Am. Acad. Dermatol. 65 (2011), e179–e193, 10.1016/j.jaad.2010.06.018.
119. Williams, H.J., Egger, M.J., Singer, J.Z., Willkens, R.F., Kalunian, K.C., Clegg, D.O., Skosey, J.L., Brooks, R.H., Alarcón, G.S., Steen, V.D., Comparison of hydroxychloroquine and placebo in the treatment of the arthropathy of mild systemic lupus erythematosus. J. Rheumatol. 21 (1994), 1457–1462 http://www.ncbi.nlm.nih.gov/pubmed/7983646.
120. Babary, H., Liu, X., Ayatollahi, Y., Chen, X.P., Doo, L., Uppaluru, L.K., Kwak, M.K., Kulaga, C., Modjinou, D., Olech, E., Yoo, J.W., Favorable effects of hydroxychloroquine on serum low density lipid in patients with systemic lupus erythematosus: a systematic review and meta-analysis. Int. J. Rheum. Dis. 21 (2018), 84–92, 10.1111/1756-185X.13159.
121. Petri, M., Lakatta, C., Magder, L., Goldman, D., Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: a longitudinal data analysis. Am. J. Med. 96 (1994), 254–259, 10.1016/0002-9343(94)90151-1.
122. Cairoli, E., Rebella, M., Danese, N., Garra, V., Borba, E.F., Hydroxychloroquine reduces low-density lipoprotein cholesterol levels in systemic lupus erythematosus: a longitudinal evaluation of the lipid-lowering effect. Lupus 21 (2012), 1178–1182, 10.1177/0961203312450084.
123. Wasko, M.C.M., McClure, C.K., Kelsey, S.F., Huber, K., Orchard, T., Toledo, F.G.S., Antidiabetogenic effects of hydroxychloroquine on insulin sensitivity and beta cell function: a randomised trial. Diabetologia 58 (2015), 2336–2343, 10.1007/s00125-015-3689-2.
124. Petri, M., Thrombosis and systemic lupus erythematosus: the Hopkins Lupus Cohort perspective. Scand. J. Rheumatol. 25 (1996), 191–193 http://www.ncbi.nlm.nih.gov/pubmed/8792794.
125. Pierangeli, S.S., Harris, E.N., In vivo models of thrombosis for the antiphospholipid syndrome. Lupus 5 (1996), 451–455, 10.1177/096120339600500524.
126. Mok, C.C., Mak, A., Ma, K.M., Bone mineral density in postmenopausal Chinese patients with systemic lupus erythematosus. Lupus 14 (2005), 106–112, 10.1191/0961203305lu2039oa.
127. Herrinton, L.J., Liu, L., Goldfien, R., Michaels, M.A., Tran, T.N., Risk of serious infection for patients with systemic lupus erythematosus starting glucocorticoids with or without antimalarials. J. Rheumatol. 43 (2016), 1503–1509, 10.3899/jrheum.150671.
128. Fang, Y., Chen, Y., Chung, T., See, L., Yu, K., Luo, S., Kuo, C., Lai, J., Hydroxychloroquine and risk of cancer in patients with primary Sjögren syndrome: propensity score matched landmark analysis. Oncotarget 8 (2017), 80461–80471, 10.18632/oncotarget.19057.
129. Wolfe, F., Marmor, M.F., Rates and predictors of hydroxychloroquine retinal toxicity in patients with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Care Res. (Hoboken). 62 (2010), 775–784, 10.1002/acr.20133.
130. Marmor, M.F., Kellner, U., Lai, T.Y.Y., Lyons, J.S., Mieler, W.F., American Academy of Ophthalmology, Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology 118 (2011), 415–422, 10.1016/j.ophtha.2010.11.017.
131. Wang, Y., Zhu, J., DeLuca, H.F., Where is the vitamin D receptor?. Arch. Biochem. Biophys. 523 (2012), 123–133, 10.1016/j.abb.2012.04.001.
132. Daniel, C., Sartory, N.A., Zahn, N., Radeke, H.H., Stein, J.M., Immune modulatory treatment of trinitrobenzene sulfonic acid colitis with calcitriol is associated with a change of a T helper (Th) 1/Th17 to a Th2 and regulatory T cell profile. J. Pharmacol. Exp. Ther. 324 (2008), 23–33, 10.1124/jpet.107.127209.
133. Yu, S., Cantorna, M.T., The vitamin D receptor is required for iNKT cell development. Proc. Natl. Acad. Sci. U. S. A. 105 (2008), 5207–5212, 10.1073/pnas.0711558105.
134. V Bonventre, J., Antifibrotic vitamin D analogs., 123, 2013, 22–25, 10.1172/JCI72748.4570.
135. Der, E., Suryawanshi, H., Ranabothu, S., Goilav, B., Belmont, H.M., Izmirly, P., Bornkamp, N., Jordan, N., Wang, T., Wu, M., James, J., Guthridge, J., Raychaudhuri, S., Tuschl, T., Buyon, J., Putterman, C., Kidney and skin single-cell RNA sequencing in lupus nephritis provides mechanistic insights and novel potential biomarkers. Arthr. Rheumatol., 69(suppl), 2017 https://acrabstracts.org/abstract/kidney-and-skin-single-cell-rna-sequencing-in-lupus-nephritis-provides-mechanistic-insights-and-novel-potential-biomarkers/.
136. Shi, Y., Liu, T., Yao, L., Xing, Y., Zhao, X., Fu, J., Xue, X., Chronic Vitamin D deficiency induces lung fibrosis through activation of the renin-angiotensin system. Sci. Rep., 7, 2017, 1, 10.1038/s41598-017-03474-6.
137. Ruiz-irastorza, G., Egurbide, M.V., Olivares, N., Martinez-Berriotxoa, A., Aguirre, C., Vitamin D deficiency in systemic lupus erythematosus: prevalence, predictors and clinical consequences. Rheumatology 47 (2008), 920–923, 10.1093/rheumatology/ken121.
138. Yang, C.Y., Leung, P.S.C., Adamopoulos, I.E., Gershwin, M.E., The implication of vitamin D and autoimmunity: a comprehensive review. Clin. Rev. Allergy Immunol. 45 (2013), 217–226, 10.1007/s2016-013-8361-3.
139. Mok, C.C., Vitamin D and systemic lupus erythematosus: an update. Expert Rev. Clin. Immunol. 9 (2013), 453–463, 10.1586/eci.13.19.
140. Amital, H., Szekanecz, Z., Szücs, G., Dankó, K., Nagy, E., Csépány, T., Kiss, E., Rovensky, J., Tuchynova, A., Kozakova, D., Doria, A., Corocher, N., Agmon-Levin, N., Barak, V., Orbach, H., Zandman-Goddard, G., Shoenfeld, Y., Serum concentrations of 25-OH vitamin D in patients with systemic lupus erythematosus (SLE) are inversely related to disease activity: is it time to routinely supplement patients with SLE with vitamin D?. Ann. Rheum. Dis. 69 (2010), 1155–1157, 10.1136/ard.2009.120329.
141. Andreoli, L., Piantoni, S., Dall'Ara, F., Allegri, F., Meroni, P.L., Tincani, A., Vitamin D and antiphospholipid syndrome. Lupus 21 (2012), 736–740, 10.1177/0961203312446386.
142. Piantoni, S., Andreoli, L., Allegri, F., Meroni, P.L., Tincani, A., Low levels of vitamin D are common in primary antiphospholipid syndrome with thrombotic disease. Reumatismo 64 (2012), 307–313, 10.4081/reumatismo.2012.307.
143. Petri, M., Bello, K.J., Fang, H., Magder, L.S., Vitamin D in systemic lupus erythematosus: modest association with disease activity and the urine protein-to-creatinine ratio. Arthritis Rheum. 65 (2013), 1865–1871, 10.1002/art.37953.
144. Lima, G.L., Paupitz, J., Aikawa, N.E., Takayama, L., Bonfa, E., Pereira, R.M.R., Vitamin D supplementation in adolescents and young adults with juvenile systemic lupus erythematosus for improvement in disease activity and fatigue scores: a randomized, double-blind, placebo-controlled trial. Arthritis Care Res. (Hoboken). 68 (2016), 91–98, 10.1002/acr.22621.
145. Durcan, L., Petri, M., Immunomodulators in SLE: clinical evidence and immunologic actions. J. Autoimmun. 74 (2016), 73–84, 10.1016/j.jaut.2016.06.010.
146. Labrie, F., Bélanger, A., Simard, J., Van Luu-The, Labrie, C., DHEA and peripheral androgen and estrogen formation: intracrinology. Ann. N. Y. Acad. Sci. 774 (1995), 16–28, 10.1111/j.1749-6632.1995.tb17369.x.
147. McMurray, R.W., May, W., Sex hormones and systemic lupus erythematosus: review and meta-analysis. Arthritis Rheum. 48 (2003), 2100–2110, 10.1002/art.11105.
148. Lahita, R.G., Bradlow, H.L., Ginzler, E., Pang, S., New, M., Low plasma androgens in women with systemic lupus erythematosus. Arthritis Rheum. 30 (1987), 241–248 http://www.ncbi.nlm.nih.gov/pubmed/3032210.
149. Lucas, J.A., Ahmed, S.A., Casey, M.L., MacDonald, P.C., Prevention of autoantibody formation and prolonged survival in New Zealand Black/New Zealand White F1mice fed dehydroisoandrosterone. J. Clin. Invest. 75 (1985), 2091–2093, 10.1172/JCI111929.
150. Chang, D.M., Chu, S.J., Chen, H.C., Kuo, S.Y., Lai, J.H., Dehydroepiandrosterone suppresses interleukin 10 synthesis in women with systemic lupus erythematosus. Ann. Rheum. Dis. 63 (2004), 1623–1626, 10.1136/ard.2003.016576.
151. Chen, C.C.G., Parker, C.R., Adrenal androgens and the immune system. Semin. Reprod. Med. 22 (2004), 369–377, 10.1055/s-2004-861553.
152. Dillon, J.S., Dehydroepiandrosterone, dehydroepiandrosterone sulfate and related steroids: their role in inflammatory, allergic and immunological disorders. Curr. Drug Targets Inflamm. Allergy 4 (2005), 377–385 http://www.ncbi.nlm.nih.gov/pubmed/16101547.
153. Petri, M.A., Lahita, R.G., Van Vollenhoven, R.F., Merrill, J.T., Schiff, M., Ginzler, E.M., Strand, V., Kunz, A., Gorelick, K.J., Schwartz, K.E., Effects of prasterone on corticosteroid requirements of women with systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 46 (2002), 1820–1829, 10.1002/art.10364.
154. Sanchez-Guerrero, J., Fragoso-Loyo, H.E., Neuwelt, C.M., Wallace, D.J., Ginzler, E.M., Sherrer, Y.R.S., McIlwain, H.H., Freeman, P.G., Aranow, C., Petri, M.A., Deodhar, A.A., Blanton, E., Manzi, S., Kavanaugh, A., Lisse, J.R., Ramsey-Goldman, R., McKay, J.D., Kivitz, A.J., Mease, P.J., Winkler, A.E., Kahl, L.E., Lee, A.H., Furie, R.A., Strand, C.V., Lou, L., Ahmed, M., Quarles, B., Schwartz, K.E., Effects of prasterone on bone mineral density in women with active systemic lupus erythematosus receiving chronic glucocorticoid therapy. J. Rheumatol. 35 (2008), 1567–1575.
155. Cain, D.W., Cidlowski, J.A., Immune regulation by glucocorticoids. Nat. Rev. Immunol. 17 (2017), 233–247, 10.1038/nri.2017.1.
156. Hahn, B.H., McMahon, M.A., Wilkinson, A., Wallace, W.D., Daikh, D.I., Fitzgerald, J.D., Karpouzas, G.A., Merrill, J.T., Wallace, D.J., Yazdany, J., Ramsey-Goldman, R., Singh, K., Khalighi, M., Choi, S.I., Gogia, M., Kafaja, S., Kamgar, M., Lau, C., Martin, W.J., Parikh, S., Peng, J., Rastogi, A., Chen, W., Grossman, J.M., American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res. 64 (2012), 797–808, 10.1002/acr.21664.
157. Bertsias, G.K., Tektonidou, M., Amoura, Z., Aringer, M., Bajema, I., Berden, J.H.M., Boletis, J., Cervera, R., Dörner, T., Doria, A., Ferrario, F., Floege, J., Houssiau, F.A., Ioannidis, J.P.A., Isenberg, D.A., Kallenberg, C.G.M., Lightstone, L., Marks, S.D., Martini, A., Moroni, G., Neumann, I., Praga, M., Schneider, M., Starra, A., Tesar, V., Vasconcelos, C., Van Vollenhoven, R.F., Zakharova, H., Haubitz, M., Gordon, C., Jayne, D., Boumpas, D.T., Joint european league against rheumatism and european renal association-european dialysis and transplant association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann. Rheum. Dis. 71 (2012), 1771–1782, 10.1136/annrheumdis-2012-201940.
158. Condon, M.B., Ashby, D., Pepper, R.J., Cook, H.T., Levy, J.B., Griffith, M., Cairns, T.D., Lightstone, L., Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. Ann. Rheum. Dis. 72 (2013), 1280–1286, 10.1136/annrheumdis-2012-202844.
159. Dooley, M., Pendergraft, W.I., Ginzler, E., Olsen, N., Tumlin, J., Rovin, B., Houssiau, F., Wofsy, D., Isenberg, D., Solomons, N., Huizinga, R., Speed of remission with the use of voclosporin, MMF and low dose steroids: results of a global lupus nephritis study [abstract]. Arthr. Rheumatol., 68(suppl), 2016 https://acrabstracts.org/abstract/speed-of-remission-with-the-use-of-voclosporin-mmf-and-low-dose-steroids-results-of-a-global-lupus-nephritis-study/.
160. Singh, J.A., Hossain, A., Kotb, A., Oliveira, A., Mudano, A.S., Grossman, J., Winthrop, K., Wells, G.A., Treatments for lupus nephritis: a systematic review and network metaanalysis. J. Rheumatol. 43 (2016), 1801–1815, 10.3899/jrheum.160041.
161. Gladman, D.D., Urowitz, M.B., Rahman, P., Ibañez, D., Tam, L.-S., Accrual of organ damage over time in patients with systemic lupus erythematosus. J. Rheumatol. 30 (2003), 1955–1959 http://www.ncbi.nlm.nih.gov/pubmed/12966597.
162. Magder, L.S., Petri, M., Incidence of and risk factors for adverse cardiovascular events among patients with systemic lupus erythematosus. Am. J. Epidemiol. 176 (2012), 708–719, 10.1093/aje/kws130.
163. Thamer, M., Hernán, M.A., Zhang, Y., Cotter, D., Petri, M., Prednisone, lupus activity, and permanent organ damage. J. Rheumatol. 36 (2009), 560–564, 10.3899/jrheum.080828.
164. Zonana-Nacach, A., Barr, S.G., Magder, L.S., Petri, M., Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis Rheum. 43 (2000), 1801–1808, 10.1002/1529-0131(200008)43:8<1801::AID-ANR16>3.0.CO;2-O.
165. Danowski, A., Magder, L., Petri, M., Flares in Lupus: outcome Assessment Trial (FLOAT), a comparison between oral methylprednisolone and intramuscular triamcinolone. J. Rheumatol. 33 (2006), 57–60.
166. Frangou, E.A., Bertsias, G., Boumpas, D.T., Cytotoxic-immunosuppressive drug treatment. Tsokos, G.C., (eds.) Syst. Lupus Erythematosus Basic, Appl. Clin. Asp., 2016, Elsevier.
167. Steinberg, A.D., Decker, J.L., A double-blind controlled trial comparing cyclophosphamide, azathioprine and placebo in the treatment of lupus glomerulonephritis. Arthritis Rheum. 17 (1974), 923–937, 10.1002/art.1780170602.
168. Austin, H.A., Klippel, J.H., Balow, J.E., Le Riche, N.G.H., Steinberg, A.D., Plotz, P.H., Decker, J.L., Therapy of lupus nephritis. N. Engl. J. Med. 314 (1986), 614–619, 10.1056/NEJM198603063141004.
169. McCune, W.J., Golbus, J., Zeldes, W., Bohlke, P., Dunne, R., Fox, D.A., Clinical and immunologic effects of monthly administration of intravenous cyclophosphamide in severe systemic lupus erythematosus. N. Engl. J. Med. 318 (1988), 1423–1431, 10.1056/NEJM198806023182203.
170. Tokunaga, M., Saito, K., Kawabata, D., Imura, Y., Fujii, T., Nakayamada, S., Tsujimura, S., Nawata, M., Iwata, S., Azuma, T., Mimori, T., Tanaka, Y., Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann. Rheum. Dis. 66 (2007), 470–475, 10.1136/ard.2006.057885.
171. Magro-Checa, C., Zirkzee, E.J., Huizinga, T.W., Steup-Beekman, G.M., Management of neuropsychiatric systemic lupus erythematosus: current approaches and future perspectives. Drugs 76 (2016), 459–483, 10.1007/s40265-015-0534-3.
172. Mok, C.C., Con: cyclophosphamide for the treatment of lupus nephritis. Nephrol. Dial. Transplant. 31 (2016), 1053–1057, 10.1093/ndt/gfw068.
173. Tiede, I., Fritz, G., Strand, S., Poppe, D., Dvorsky, R., Strand, D., Lehr, H.A., Wirtz, S., Becker, C., Atreya, R., Mudter, J., Hildner, K., Bartsch, B., Holtmann, M., Blumberg, R., Walczak, H., Iven, H., Galle, P.R., Ahmadian, M.R., Neurath, M.F., CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J. Clin. Invest. 111 (2003), 1133–1145, 10.1172/JCI200316432.Introduction.
174. Ginzler, E., Sharon, E., Diamond, H., Kaplan, D., Long-term maintenance therapy with azathioprine in systemic lupus erythematosus. Arthritis Rheum. 18 (1975), 27–34 http://www.ncbi.nlm.nih.gov/pubmed/1115745.
175. Sztejnbok, M., Stewart, A., Diamond, H., Kaplan, D., Azathioprine in the treatment of systemic lupus erythematosus. A controlled study. Arthritis Rheum. 14 (1971), 639–645.
176. Grootscholten, C., Ligtenberg, G., Hagen, E.C., Van Den Wall Bake, A.W.L., De Glas-Vos, J.W., Bijl, M., Assmann, K.J., Bruijn, J.A., Weening, J.J., Van Houwelingen, H.C., Derksen, R.H.W.M., Berden, J.H.M., Azathioprine/methylprednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial. Kidney Int. 70 (2006), 732–742, 10.1038/sj.ki.5001630.
177. Grootscholten, C., Bajema, I.M., Florquin, S., Steenbergen, E.J., Peutz-Kootstra, C.J., Goldschmeding, R., Bijl, M., Hagen, E.C., Van Houwelingen, H.C., Derksen, R.H.W.M., Berden, J.H.M., Treatment with cyclophosphamide delays the progression of chronic lesions more effectively than does treatment with azathioprine plus methylprednisolone in patients with proliferative lupus nephritis. Arthritis Rheum. 56 (2007), 924–937, 10.1002/art.22449.
178. Dooley, M.A., Jayne, D., Ginzler, E.M., Isenberg, D., Olsen, N.J., Wofsy, D., Eitner, F., Appel, G.B., Contreras, G., Lisk, L., Solomons, N., Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N. Engl. J. Med. 365 (2011), 1886–1895, 10.1056/NEJMoa1014460.
179. Houssiau, F.A., D'Cruz, D., Sangle, S., Remy, P., Vasconcelos, C., Petrovic, R., Fiehn, C., Garrido, E.D.R., Gilboe, I.M., Tektonidou, M., Blockmans, D., Ravelingien, I., Le Guern, V., Depresseux, G., Guillevin, L., Cervera, R., Abramowicz, D., Atzeni, F., Danieli, M.G., De Clercq, L., De Keyser, F., Delahousse, M., Espinosa, G., Golstein, M., Hirsch, M., Karras, A., Lang, P., Marchal, M., Marinho, A., Max, R., Peeters, P., Petera, P., Quémeneur, T., Raeman, F., Sarzi-Puttini, P., De Santis, L.V., Verresen, L., Weiss, L., Westhovens, R., Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial. Ann. Rheum. Dis. 69 (2010), 2083–2089, 10.1136/ard.2010.131995.
180. Griffiths, B., Emery, P., Ryan, V., Isenberg, D., Akil, M., Thompson, R., Maddison, P., Griffiths, I.D., Lorenzi, A., Miles, S., Situnayake, D., Teh, L.S., Plant, M., Hallengren, C., Nived, O., Sturfelt, G., Chakravarty, K., Tait, T., Gordon, C., The BILAG multi-centre open randomized controlled trial comparing ciclosporin vs azathioprine in patients with severe SLE. Rheumatology (Oxford) 49 (2010), 723–732, 10.1093/rheumatology/kep396.
181. Ordi-Ros, J., Sáez-Comet, L., Pérez-Conesa, M., Vidal, X., Mitjavila, F., Castro Salomó, A., Cuquet Pedragosa, J., Ortiz-Santamaria, V., Mauri Plana, M., Cortés-Hernández, J., Enteric-coated mycophenolate sodium versus azathioprine in patients with active systemic lupus erythematosus: a randomised clinical trial. Ann. Rheum. Dis. 76 (2017), 1575–1582, 10.1136/annrheumdis-2016-210882.
182. Lateef, A., Petri, M., Systemic lupus erythematosus and pregnancy. Rheum. Dis. Clin. N. Am. 43 (2017), 215–226, 10.1016/j.rdc.2016.12.009.
183. De Boer, N.K.H., Jarbandhan, S.V.A., De Graaf, P., Mulder, C.J.J., Van Elburg, R.M., Van Bodegraven, A.A., Azathioprine use during pregnancy: unexpected intrauterine exposure to metabolites. Am. J. Gastroenterol. 101 (2006), 1390–1392, 10.1111/j.1572-0241.2006.00538.x.
184. Brown, P.M., Pratt, A.G., Isaacs, J.D., Mechanism of action of methotrexate in rheumatoid arthritis, and the search for biomarkers. Nat. Rev. Rheumatol. 12 (2016), 731–742, 10.1038/nrrheum.2016.175.
185. Miescher, P.A., Riethmueller, D., Diagnosis and treatment of systemic lupus erythematosus. Semin. Hematol. 2 (1965), 1–28 http://www.ncbi.nlm.nih.gov/pubmed/14268735.
186. Sakthiswary R, S.E., Methotrexate in systemic lupus erythematosus: a systematic review of its efficacy. Lupus 23:3 (2014), 225–235 http://www.ncbi.nlm.nih.gov/pubmed/14268735.
187. Fortin, P.R., Abrahamowicz, M., Ferland, D., Lacaille, D., Smith, C.D., Zummer, M., Steroid-sparing effects of methotrexate in systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 59 (2008), 1796–1804, 10.1002/art.24068.
188. Allison, A., Mechanisms of action of mycophenolate mofetil. Lupus 14 (2005), 2–8, 10.1191/0961203305LU2109OA.
189. Chan, T.M., Li, F.K., Tang, C.S.O., Wong, R.W.S., Fang, G.X., Ji, Y.L., Lau, C.S., Wong, A.K.M., Tong, M.K.L., Chan, K.W., Lai, K.N., Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. N. Engl. J. Med. 343 (2000), 1156–1162, 10.1056/NEJM200010193431604.
190. Ginzler, E.M., Dooley, M.A., Aranow, C., Kim, M.Y., Buyon, J., Merrill, J.T., Petri, M., Gilkeson, G.S., Wallace, D.J., Weisman, M.H., Appel, G.B., Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N. Engl. J. Med. 353 (2005), 2219–2228, 10.1056/NEJMoa043731.
191. Appel, G.B., Contreras, G., Dooley, M.A., Ginzler, E.M., Isenberg, D., Jayne, D., Li, L.-S., Mysler, E., Sanchez-Guerrero, J., Solomons, N., Wofsy, D., Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J. Am. Soc. Nephrol. 20 (2009), 1103–1112, 10.1681/ASN.2008101028.
192. Tunnicliffe, D.J., Palmer, S.C., Henderson, L., Masson, P., Craig, J.C., Tong, A., Singh-Grewal, D., Flanc, R.S., Roberts, M.A., Webster, A.C., Strippoli, G.F., Immunosuppressive treatment for proliferative lupus nephritis. Cochrane Database Syst. Rev., 2018, 10.1002/14651858.CD002922.pub4.
193. Mok, C.C., Mycophenolate mofetil for non-renal manifestations of systemic lupus erythematosus: a systematic review. Scand. J. Rheumatol. 36 (2007), 329–337, 10.1080/03009740701607042.
194. Ginzler, E.M., Wofsy, D., Isenberg, D., Gordon, C., Lisk, L., Dooley, M.A., Nonrenal disease activity following mycophenolate mofetil or intravenous cyclophosphamide as induction treatment for lupus nephritis: findings in a multicenter, prospective, randomized, open-label, parallel-group clinical trial. Arthritis Rheum. 62 (2010), 211–221, 10.1002/art.25052.
195. Mok, C.C., Calcineurin inhibitors in systemic lupus erythematosus. Best Pract. Res. Clin. Rheumatol. 31 (2017), 429–438, 10.1016/j.berh.2017.09.010.
196. Ikezumi, Y., Kanno, K., Koike, H., Tomita, M., Uchiyama, M., Shimizu, F., Kawachi, H., FK506 ameliorates proteinuria and glomerular lesions induced by anti-Thy 1.1 monoclonal antibody 1-22-3. Kidney Int. 61 (2002), 1339–1350, 10.1046/j.1523-1755.2002.00259.x.
197. Liao, R., Liu, Q., Zheng, Z., Fan, J., Peng, W., Kong, Q., He, H., Yang, S., Chen, W., Tang, X., Yu, X., Tacrolimus protects podocytes from injury in lupus nephritis partly by stabilizing the cytoskeleton and inhibiting podocyte apoptosis. PloS One 10 (2015), 1–16, 10.1371/journal.pone.0132724.
198. Faul, C., Donnelly, M., Merscher-Gomez, S., Chang, Y.H., Franz, S., Delfgaauw, J., Chang, J.M., Choi, H.Y., Campbell, K.N., Kim, K., Reiser, J., Mundel, P., The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat. Med. 14 (2008), 931–938, 10.1038/nm.1857.
199. Krämer, B.K., Montagnino, G., del Castillo, D., Margreiter, R., Sperschneider, H., Olbricht, C.J., Krüger, B., Ortuño, J., Köhler, H., Kunzendorf, U., Stummvoll, H.K., Tabernero, J.M., Mühlbacher, F., Rivero, M., Arias, M., Dietl, K.H., del Castillo, D., Pascual, J., Olbrícht, C., Kammerl, M., Krüger, B., Köhler, K., Sester, U., Mühlbacher, F., Kunzendorf, U., Hauser, I., Ponticelli, C., Bonomini, V., Tabernero, J.M., Rivero, M., Ancona, E., Calconi, G., Cambi, V., la Greca, G., Mosca, F., Selvaggi, F., Meurisse, M., Detry, O., González Molina, M., Piccoli, G., Salvadori, M., Schilling, M., Raedelli, C., Arns, W., Suarez, F., Rodríguez Algarra, G., Asensio, C., Maiorca, R., Ancona, G., Sparacino, V., Morales, J.M., Gutierrez, J.A., Lauzurica, R., Verpooten, G.A., Sennesael, J., Heidecke, C., García, J., Capdevila, L., Abendroth, D., Biesenbach, G., Altieri, P., Sorba, G., Valente, U., Castagneto, M., Purroy, A., Duhoux, P., Kremar, C., Stiegler, G., Schleibner, S., Efficacy and safety of tacrolimus compared with cyclosporin A microemulsion in renal transplantation: 2 year follow-up results. Nephrol. Dial. Transplant. 20 (2005), 968–973, 10.1093/ndt/gfh739.
200. Li, X., Ren, H., Zhang, Q., Zhang, W., Wu, X., Xu, Y., Shen, P., Chen, N., Mycophenolate mofetil or tacrolimus compared with intravenous cyclophosphamide in the induction treatment for active lupus nephritis. Nephrol. Dial. Transplant. 27 (2012), 1467–1472, 10.1093/ndt/gfr484.
201. Chen, W., Tang, X., Liu, Q., Chen, W., Fu, P., Liu, F., Liao, Y., Yang, Z., Zhang, J., Chen, J., Lou, T., Fu, J., Kong, Y., Liu, Z., Fan, A., Rao, S., Li, Z., Yu, X., Short-term outcomes of induction therapy with tacrolimus versus cyclophosphamide for active lupus nephritis: a multicenter randomized clinical trial. Am. J. Kidney Dis. 57 (2011), 235–244, 10.1053/j.ajkd.2010.08.036.
202. Závada, J., Pešičkova, S.S., Ryšavá, R., Olejárova, M., Horák, P., Hrnčíř, Z., Rychlík, I., Havrda, M., Vítová, J., Lukáč, J., Rovenský, J., Tegzova, D., Böhmova, J., Zadražil, J., Hána, J., Dostál, C., Tesar, V., Cyclosporine A or intravenous cyclophosphamide for lupus nephritis: the Cyclofa-Lune study. Lupus 19 (2010), 1281–1289, 10.1177/0961203310371155.
203. Závada, J., Pešičková, S.S., Ryšavá, R., Horák, P., Hrnčíř, Z., Lukáč, J., Rovenský, J., Vítová, J., Havrda, M., Rychlík, I., Böhmova, J., Vlasáková, V., Slatinská, J., Zadražil, J., Olejárová, M., Tegzova, D., Tesar, V., Extended follow-up of the CYCLOFA-LUNE trial comparing two sequential induction and maintenance treatment regimens for proliferative lupus nephritis based either on cyclophosphamide or on cyclosporine A. Lupus 23 (2014), 69–74, 10.1177/0961203313511555.
204. Hannah, J., Casian, A., D'Cruz, D., Tacrolimus use in lupus nephritis: a systematic review and meta-analysis. Autoimmun. Rev. 15 (2016), 93–101, 10.1016/j.autrev.2015.09.006.
205. Mok, C.C., Ying, K.Y., Yim, C.W., Siu, Y.P., Tong, K.H., To, C.H., Ng, W.L., Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: a randomised controlled trial and long-term follow-up. Ann. Rheum. Dis. 75 (2016), 30–36, 10.1136/annrheumdis-2014-206456.
206. Lanata, C.M., Mahmood, T., Fine, D.M., Petri, M., Combination therapy of mycophenolate mofetil and tacrolimus in lupus nephritis. Lupus 19 (2010), 935–940, 10.1177/0961203310365714.
207. Cortés-Hernández, J., Torres-Salido, M.T., Medrano, A.S., Tarrés, M.V., Ordi-Ros, J., Long-term outcomes - mycophenolate mofetil treatment for lupus nephritis with addition of tacrolimus for resistant cases. Nephrol. Dial. Transplant. 25 (2010), 3939–3948, 10.1093/ndt/gfq322.
208. Mok, C.C., To, C.H., Yu, K.L., Ho, L.Y., Combined low-dose mycophenolate mofetil and tacrolimus for lupus nephritis with suboptimal response to standard therapy: a 12-month prospective study. Lupus 22 (2013), 1135–1141, 10.1177/0961203313502864.
209. Liu, Z., Zhang, H., Liu, Z., Xing, C., Fu, P., Ni, Z., Chen, J., Lin, H., Liu, F., He, Y., He, Y., Miao, L., Chen, N., Li, Y., Gu, Y., Shi, W., Hu, W., Liu, Z., Bao, H., Zeng, C., Zhou, M., Multitarget therapy for induction treatment of lupus nephritis: a randomized trial. Ann. Intern. Med. 162 (2015), 18–26, 10.7326/M14-1030.
210. Moroni, G., Doria, A., Mosca, M., Alberighi, O.D.C., Ferraccioli, G., Todesco, S., Manno, C., Altieri, P., Ferrara, R., Greco, S., Ponticelli, C., A randomized pilot trial comparing cyclosporine and azathioprine for maintenance therapy in diffuse lupus nephritis over four years. Clin. J. Am. Soc. Nephrol. 1 (2006), 925–932, 10.2215/CJN.02271205.
211. Chen, W., Liu, Q., Chen, W., Tang, X., Fu, P., Liu, F., Liao, Y., Yang, Z., Zhang, J., Chen, J., Lou, T., Fu, J., Kong, Y., Liu, Z., Li, Z., Yu, X., Outcomes of maintenance therapy with tacrolimus versus azathioprine for active lupus nephritis: a multicenter randomized clinical trial. Lupus 21 (2012), 944–952, 10.1177/0961203312442259.
212. Radhakrishnan, J., Kunis, C.L., D'Agati, V., Appel, G.B., Cyclosporine treatment of lupus membranous nephropathy. Clin. Nephrol. 42 (1994), 147–154 http://www.ncbi.nlm.nih.gov/pubmed/7994932.
213. Yap, D.Y., Yu, X., Chen, X.M., Lu, F., Chen, N., Li, X.W., Tang, C.S., Chan, T.M., Pilot 24 month study to compare mycophenolate mofetil and tacrolimus in the treatment of membranous lupus nephritis with nephrotic syndrome. Nephrology 17 (2012), 352–357, 10.1111/j.1440-1797.2012.01574.x.
214. Hallegua, D., Wallace, D.J., Metzger, A.L., Rinaldi, R.Z., Klinenberg, J.R., Cyclosporine for lupus membranous nephritis: experience with ten patients and review of the literature. Lupus 9 (2000), 241–251, 10.1191/096120300680198935.
215. Austin, H.A., Illei, G.G., Braun, M.J., Balow, J.E., Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy. J. Am. Soc. Nephrol. 20 (2009), 901–911, 10.1681/ASN.2008060665.
216. Busque, S., Cantarovich, M., Mulgaonkar, S., Gaston, R., Gaber, A.O., Mayo, P.R., Ling, S., Huizinga, R.B., Meier-Kriesche, H.U., The PROMISE study: a phase 2b multicenter study of voclosporin (ISA247) versus tacrolimus in de Novo kidney transplantation. Am. J. Transplant. 11 (2011), 2675–2684, 10.1111/j.1600-6143.2011.03763.x.
217. Parikh, S., Pendergraft, W., Tumlin, J., Saxena, R., Solomons, N., Huizinga, R., Treatment of active Lupus nephritis with Voclosporin: 48 week data from the aura-LV study. Am. J. Kidney Dis. Conf. Natl. Kidney Found., 69, 2017, A2, 10.1053/j.ajkd.2017.03.005 2017 Spring Clin. Meet. United States.
218. Cobo-Ibáñez, T., Loza-Santamaría, E., Pego-Reigosa, J.M., Marqués, A.O., Rúa-Figueroa, Í., Fernández-Nebro, A., Cáliz, R.C., López Longo, F.J., Muñoz-Fernández, S., Efficacy and safety of rituximab in the treatment of non-renal systemic lupus erythematosus: a systematic review. Semin. Arthritis Rheum. 44 (2015), 175–185, 10.1016/j.semarthrit.2014.04.002.
219. Lan, L., Han, F., Chen, J., Efficacy and safety of rituximab therapy for systemic lupus erythematosus: a systematic review and meta-analysis. J. Zhejiang Univ. Sci. B. 13 (2012), 731–744, 10.1631/jzus.B1200057.
220. Merrill, J.T., Neuwelt, C.M., Wallace, D.J., Shanahan, J.C., Latinis, K.M., Oates, J.C., Utset, T.O., Gordon, C., Isenberg, D.A., Hsieh, H.J., Zhang, D., Brunetta, P.G., Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 62 (2010), 222–233, 10.1002/art.27233.
221. Rovin, B.H., Furie, R., Latinis, K., Looney, R.J., Fervenza, F.C., Sanchez-Guerrero, J., Maciuca, R., Zhang, D., Garg, J.P., Brunetta, P., Appel, G., LUNAR Investigator Group, Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum. 64 (2012), 1215–1226, 10.1002/art.34359.
222. John Looney, R., Anolik, J., Sanz, I., A perspective on B-cell-targeting therapy for SLE. Mod. Rheumatol. 20 (2010), 1–10, 10.1007/s10165-009-0213-x.
223. Cambridge, G., Isenberg, D.A., Edwards, J.C.W., Leandro, M.J., Migone, T.-S., Teodorescu, M., Stohl, W., B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response. Ann. Rheum. Dis. 67 (2008), 1011–1016, 10.1136/ard.2007.079418.
224. Ehrenstein, M.R., Wing, C., The BAFFling effects of rituximab in lupus: danger ahead?. Nat. Rev. Rheumatol. 12 (2016), 367–372, 10.1038/nrrheum.2016.18.
225. Carter, L.M., Isenberg, D.A., Ehrenstein, M.R., Elevated serum BAFF levels are associated with rising anti-double-stranded DNA antibody levels and disease flare following B cell depletion therapy in systemic lupus erythematosus. Arthritis Rheum. 65 (2013), 2672–2679, 10.1002/art.38074.
226. Kraaij, T., Kamerling, S.W.A., de Rooij, E.N.M., van Daele, P.L.A., Bredewold, O.W., Bakker, J.A., Bajema, I.M., Scherer, H.U., Toes, R.E.M., Huizinga, T.J.W., Rabelink, T.J., van Kooten, C., Teng, Y.K.O., The NET-effect of combining rituximab with belimumab in severe systemic lupus erythematosus. J. Autoimmun. 91 (2018), 45–54, 10.1016/j.jaut.2018.03.003.
227. Aranow, C., Dall'Era, M., Byron, M., Ding, L., Smilek, D., Diamond, B., Wofsy, D., FRI0305 Phase 2 trial of induction therapy with anti-cd20 (RITUXIMAB) followed by maintenance therapy with anti-baff (BELIMUMAB) in patients with active lupus nephritis. Ann. Rheum. Dis., 77, 2018 690 LP-690 http://ard.bmj.com/content/77/Suppl_2/690.1.abstract.
228. MacKay, F., Schneider, P., Cracking the BAFF code. Nat. Rev. Immunol. 9 (2009), 491–502, 10.1038/nri2572.
229. Treml, J.F., Hao, Y., Stadanlick, J.E., Cancro, M.P., The BLyS family: toward a molecular understanding of B cell homeostasis. Cell Biochem. Biophys. 53 (2009), 1–16, 10.1007/s12013-008-9036-1.
230. Petri, M.A., van Vollenhoven, R.F., Buyon, J., Levy, R.A., Navarra, S.V., Cervera, R., Zhong, Z.J., Freimuth, W.W., Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials. Arthritis Rheum. 65 (2013), 2143–2153, 10.1002/art.37995.
231. Groom, J.R., Fletcher, C.A., Walters, S.N., Grey, S.T., Watt, S.V., Sweet, M.J., Smyth, M.J., Mackay, C.R., Mackay, F., BAFF and MyD88 signals promote a lupuslike disease independent of T cells. J. Exp. Med. 204 (2007), 1959–1971, 10.1084/jem.20062567.
232. Furie, R., Petri, M., Zamani, O., Cervera, R., Wallace, D.J., Tegzová, D., Sanchez-Guerrero, J., Schwarting, A., Merrill, J.T., Chatham, W.W., Stohl, W., Ginzler, E.M., Hough, D.R., Zhong, Z.J., Freimuth, W., Van Vollenhoven, R.F., A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 63 (2011), 3918–3930, 10.1002/art.30613.
233. Navarra, S.V., Guzmán, R.M., Gallacher, A.E., Hall, S., Levy, R.A., Jimenez, R.E., Li, E.K.M., Thomas, M., Kim, H.Y., León, M.G., Tanasescu, C., Nasonov, E., Lan, J.L., Pineda, L., Zhong, Z.J., Freimuth, W., Petri, M.A., Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 377 (2011), 721–731, 10.1016/S0140-6736(10)61354-2.
234. Van Vollenhoven, R.F., Petri, M.A., Cervera, R., Roth, D.A., Ji, B.N., Kleoudis, C.S., Zhong, Z.J., Freimuth, W., Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. Ann. Rheum. Dis. 71 (2012), 1343–1349, 10.1136/annrheumdis-2011-200937.
235. Furie, R., Khamashta, M., Merrill, J.T., Werth, V.P., Kalunian, K., Brohawn, P., Illei, G.G., Drappa, J., Wang, L., Yoo, S., Anifrolumab, an anti–interferon-α receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus. Arthr. Rheumatol. 69 (2017), 376–386, 10.1002/art.39962.
236. AstraZeneca, Update on TULIP 1 Phase III Trial for Anifrolumab in Systemic Lupus Erythematosus, (n.d.). https://www.astrazeneca.com/media-centre/press-releases/2018/update-on-tulip-1-phase-iii-trial-for-anifrolumab-in-systemic-lupus-erythematosus-31082018.html.
237. Yang, X.O., Panopoulos, A.D., Nurieva, R., Seon, H.C., Wang, D., Watowich, S.S., Dong, C., STAT3 regulates cytokine-mediated generation of inflammatory helper T cells. J. Biol. Chem. 282 (2007), 9358–9363, 10.1074/jbc.C600321200.
238. Ma, C., Avery, D., Chan, A., Batten, M., Bustamante, J., Boisson-Dupuis, S., Arkwright, P., Kreins, A., Averbuch, D., Engelhard, D., Magdorf, K., Kilic, S., Minegishi, Y., Nonoyama, S., French, M., Choo, S., Smart, J., Peake, J., Wong, M., Gray, P., Cook, M., Fulcher, D., Casanova, J.-L., Deenick, E., Tangye, S., Functional STAT3 deficiency compromises the generation of human T follicular helper cells. Blood 119 (2012), 3997–4008, 10.1182/blood-2011-11-392985 The.
239. Ueno, H., Banchereau, J., Vinuesa, C.G., Pathophysiology of T follicular helper cells in humans and mice. Nat. Immunol. 16 (2015), 142–152, 10.1038/ni.3054.
240. Shaltout, A.S., Sayed, D., Badary, M.S., Nafee, A.M., El Zohri, M.H., Bakry, R., Ahmed, S.H., Effect of IL6 and IL23 on double negative T cells and anti ds-DNA in systemic lupus erythematosus patients. Hum. Immunol. 77 (2016), 937–943, 10.1016/j.humimm.2016.06.007.
241. Dai, H., He, F., Tsokos, G.C., Kyttaris, V.C., IL-23 limits the production of IL-2 and promotes autoimmunity in lupus. J. Immunol. 199 (2017), 903–910, 10.4049/jimmunol.1700418.
242. van Vollenhoven, R., Hahn, B., Tsokos, G., Wagner, C., Lipsky, P., Hsu, B., Chevrier, M., Gordon, R., Triebel, M., Rose, S., S7A:8 Efficacy and safety of ustekinumab, an interleukin 12/23 inhibitor, in patients with active systemic lupus erythematosus: results of a phase 2, randomised placebo-controlled study. Lupus Sci. Med., 5, 2018 A28 LP-A29 http://lupus.bmj.com/content/5/Suppl_1/A28.abstract.
243. Gadina, M., Johnson, C., Schwartz, D., Bonelli, M., Hasni, S., Kanno, Y., Changelian, P., Laurence, A., O'Shea, J.J., Translational and clinical advances in JAK-STAT biology: the present and future of jakinibs. J. Leukoc. Biol., 2018, 1–16, 10.1002/JLB.5RI0218-084R.
244. Wallace, D.J., Furie, R.A., Tanaka, Y., Kalunian, K.C., Mosca, M., Petri, M.A., Dörner, T., Cardiel, M.H., Bruce, I.N., Gomez, E., Carmack, T., DeLozier, A.M., Janes, J.M., Linnik, M.D., de Bono, S., Silk, M.E., Hoffman, R.W., Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet 392 (2018), 222–231, 10.1016/S0140-6736(18)31363-1.
245. Dall'Era, M., Chakravarty, E., Wallace, D., Genovese, M., Weisman, M., Kavanaugh, A., Kalunian, K., Dhar, P., Vincent, E., Pena-Rossi, C., Wofsy, D., Alum, N., Dubois, A., Kinnman, N., Picard, M., Bortolotti, A., O'Grady, L., Hill, J., Nestorov, I., Salmon, E., Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial. Arthritis Rheum. 56 (2007), 4142–4150, 10.1002/art.23047.
246. Merrill, J.T., Wallace, D.J., Wax, S., Kao, A., Fraser, P.A., Chang, P., Isenberg, D., Efficacy and safety of atacicept in patients with systemic lupus erythematosus: results of a twenty-four–week, multicenter, randomized, double-blind, placebo-controlled, parallel-arm, phase IIb study. Arthr. Rheumatol. 70 (2018), 266–276, 10.1002/art.40360.
247. Wallace, D.J., Improving the prognosis of SLE without prescribing lupus drugs and the primary care paradox. Lupus 17 (2008), 91–92, 10.1177/0961203307086267.
248. Kuhn, A., Gensch, K., Haust, M., Meuth, A.M., Boyer, F., Dupuy, P., Lehmann, P., Metze, D., Ruzicka, T., Photoprotective effects of a broad-spectrum sunscreen in ultraviolet-induced cutaneous lupus erythematosus: a randomized, vehicle-controlled, double-blind study. J. Am. Acad. Dermatol. 64 (2011), 37–48, 10.1016/j.jaad.2009.12.053.
249. Wolfe, F., Petri, M., Alarcón, G.S., Goldman, J., Chakravarty, E.F., Katz, R.S., Karlson, E.W., Fibromyalgia, systemic lupus erythematosus (SLE), and evaluation of SLE activity. J. Rheumatol. 36 (2009), 82–88, 10.3899/jrheum.080212.
250. Torrente-Segarra, V., Salman-Monte, T.C., Rúa-Figueroa, íñigo, Pérez-Vicente, S., López-Longo, F.J., Galindo-Izquierdo, M., Calvo-Alén, J., Olivé-Marqués, A., Ibáñez-Ruán, J., Horcada, L., Sánchez-Atrio, A., Montilla, C., Rodríguez-Gómez, M., Díez-álvarez, E., Martinez-Taboada, V., Andreu, J.L., Fernández-Berrizbeitia, O., Hernández-Beriain, J.A., Gantes, M., Hernández-Cruz, B., Pecondón-Español, ángela, Marras, C., Bonilla, G., Pego-Reigosa, J.M., Blanco, R., Vela-Casasempere, P., Melero-González, R., Otón-Sánchez, T., Tornero-Muriel, E., Uriarte-Isacelaya, E., Freire-González, M., Fito-Manteca, M.C., Fernández-Nebro, A., Narváez, J., Zea-Mendoza, A., Rosas-Gómez de Salazar, J.C., Ibáñez-Barceló, M., Pérez-Venegas, J.J., de la Torre Ortega, I., Pérez, L.C., Delgado, P.C., Rodríguez-Almaraz, E., Heredia, E.S., Soler, G.S., Ramírez, C.S., Senabre Gallego, J.M., Collado, M.A., Bernal, J.A., Vilamajó, I.R., Mas, A.J., Murillo, C., Barranco, I.C., Melchor, E.G., Fontova, J.C., Manrique, M.G., Lencastre, C.G., Martínez-Losa, M.M., Almagro, R.M., González-Gay Mantecón, M.A., Martíny, I.P., del Carmen Bejerano, M., Blanco, I.V., Moreira, B., Aurrecoechea, E., Jimeno, T.R., Zamorano, ángeles A., Magro, C., álvarez, E.R., Arruabarrena, C.E., Mérida, M. ángeles A., Egües Dubuc, C.A., Fanlo, J.C., álvarez, E.D., Vitovi, C., Robles, A.L., Rodríguez, T.V., Oyarzábal, M.V.I., ángeles, M., López, B., Romero Barco, C.M., López, J.A.M., Pernaute, O.S., de Vicuña Pinedo, T.G., Expósito, M.V., de la Peña, P.G., Rubio, S.R., González Martín, J.J., Gómez, A.P., Bohórquez, C., Hajkhan, A.M., Turrión Nieves, A.I., Lois Iglesias, A.J., Boteanu, A.L., Gamir, M.L.G., Alberti, P.R., Fernández, S.M., Oliva, M.R., Stoye, C., Rodríguez, íñigo H., Rodríguez, C.M., de Aspe de la Iglesia, B., González, R.L., Sarabia, F.N., Toyos Sáenz de Miera, F.J., de la Fuente, J.L.M., Montañés, J.U., Sánchez, R.H., Pérez, R.M., Lozano, B.R., úcar Angulo, E., Lucea, M.E.R., Domínguez, L.L., Alegre Sancho, J.J., de La Morena Barrio, I., Valls, E., Ruiz, J.M., Quevedo Vila, V.E., Machín, S., Nóvoa, J., Fernández, L.S., Fibromyalgia prevalence and related factors in a large registry of patients with systemic lupus erythematosus. Clin. Exp. Rheumatol. 34 (2016), 40–47.
251. Wang, C., Schmid, C.H., Rones, R., Kalish, R., Yinh, J., Goldenberg, D.L., Lee, Y., McAlindon, T., A randomized trial of tai chi for fibromyalgia. N. Engl. J. Med. 363 (2010), 743–754, 10.1056/NEJMoa0912611.
252. Gomez-Pinilla, F., Hillman, C., The influence of exercise on cognitive abilities. Compr. Physiol. 3 (2013), 403–428, 10.1002/cphy.c110063.
253. Tench, C.M., McCarthy, J., McCurdie, I., White, P.D., D'Cruz, D.P., Fatigue in systemic lupus erythematosus: a randomized controlled trial of exercise. Rheumatology (Oxford) 42 (2003), 1050–1054, 10.1093/rheumatology/keg289.
254. Giannelou, M., Mavragani, C.P., Cardiovascular disease in systemic lupus erythematosus: a comprehensive update. J. Autoimmun. 82 (2017), 1–12, 10.1016/j.jaut.2017.05.008.
255. Petri, M., Roubenoff, R., Dallal, G.E., Nadeau, M.R., Selhub, J., Rosenberg, I.H., Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus. Lancet 348 (1996), 1120–1124, 10.1016/S0140-6736(96)03032-2.
256. Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke. JAMA, 288, 2002, 2015, 10.1001/jama.288.16.2015.
257. Humphrey, L.L., Fu, R., Rogers, K., Freeman, M., Helfand, M., Homocysteine level and coronary heart disease incidence: a systematic review and meta-analysis. Mayo Clin. Proc. 83 (2016), 1203–1212, 10.4065/83.11.1203.
258. Veeranna, V., Zalawadiya, S.K., Niraj, A., Pradhan, J., Ference, B., Burack, R.C., Jacob, S., Afonso, L., Homocysteine and reclassification of cardiovascular disease risk. J. Am. Coll. Cardiol. 58 (2011), 1025–1033, 10.1016/j.jacc.2011.05.028.
259. Yi, F., Dos Santos, E.A., Xia, M., Chen, Q.Z., Li, P.L., Li, N., Podocyte injury and glomerulosclerosis in hyperhomocysteinemic rats. Am. J. Nephrol. 27 (2007), 262–268, 10.1159/000101471.
260. Long, Y., Nie, J., Homocysteine in renal injury. Kidney Dis. (Basel, Switzerland) 2 (2016), 80–87, 10.1159/000444900 PM - 27536696 M4 - Citavi.
261. Stojan, G., Fu, W., Petri, M., Homocysteine, antiphospholipid antibodies and risk of vascular events in patients with systemic lupus erythematosus [Abstract]. Ann. Rheum. Dis., 76, 2017.
262. Ross, S.C., Densen, P., Complement deficiency states and infection: epidemiology, pathogenesis and consequences of neisserial and other infections in an immune deficiency. Medicine (Baltimore) 63 (1984), 243–273 http://www.ncbi.nlm.nih.gov/pubmed/6433145.
263. Danza, A., Ruiz-Irastorza, G., Infection risk in systemic lupus erythematosus patients: susceptibility factors and preventive strategies. Lupus 22 (2013), 1286–1294, 10.1177/0961203313493032.
264. Carli, L., Tani, C., Spera, V., Vagelli, R., Vagnani, S., Mazzantini, M., Di Munno, O., Mosca, M., Risk factors for osteoporosis and fragility fractures in patients with systemic lupus erythematosus. Lupus Sci. Med., 3, 2016, e000098, 10.1136/lupus-2015-000098.
265. Edens, C., Robinson, A.B., Systemic lupus erythematosus, bone health, and osteoporosis. Curr. Opin. Endocrinol. Diabetes Obes. 22 (2015), 422–431, 10.1097/MED.0000000000000197.
266. Borba, V.Z.C., Matos, P.G., Da Silva Viana, P.R., Fernandas, A., Sato, E.I., Lazaretti-Castro, M., High prevalence of vertebral deformity in premenopausal systemic lupus erythematosus patients. Lupus 14 (2005), 529–533, 10.1191/0961203305lu2154oa.
267. Buckley, L., Guyatt, G., Fink, H.A., Cannon, M., Grossman, J., Hansen, K.E., Humphrey, M.B., Lane, N.E., Magrey, M., Miller, M., Morrison, L., Rao, M., Robinson, A.B., Saha, S., Wolver, S., Bannuru, R.R., Vaysbrot, E., Osani, M., Turgunbaev, M., Miller, A.S., McAlindon, T., 2017 American college of rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthr. Rheumatol. 69 (2017), 1521–1537, 10.1002/art.40137.
268. Anderson, J.J.B., Kruszka, B., Delaney, J.A.C., He, K., Burke, G.L., Alonso, A., Bild, D.E., Budoff, M., Michos, E.D., Calcium intake from diet and supplements and the risk of coronary artery calcification and its progression among older adults: 10-year follow-up of the multi-ethnic study of atherosclerosis (MESA). J. Am. Heart Assoc. 5 (2016), 1–13, 10.1161/JAHA.116.003815.
269. Der, E., Ranabothu, S., Suryawanshi, H., Akat, K.M., Clancy, R., Morozov, P., Kustagi, M., Czuppa, M., Izmirly, P., Belmont, H.M., Wang, T., Jordan, N., Bornkamp, N., Nwaukoni, J., Martinez, J., Goilav, B., Buyon, J.P., Tuschl, T., Putterman, C., Single cell RNA sequencing to dissect the molecular heterogeneity in lupus nephritis. JCI Insight, 2, 2017, 10.1172/jci.insight.93009.